Palisade Bio, Inc. (PALI)

NASDAQ: PALI · IEX Real-Time Price · USD
0.399
+0.004 (0.96%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.

The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.

It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Palisade Bio, Inc.
Palisade Bio logo
Country United States
Founded 1996
Industry Biotechnology
Sector Healthcare
Employees 12
CEO J. D. Finley

Contact Details

Address:
7750 El Camino Real, Suite 5200
Carlsbad, California 92009
United States
Phone (858) 704-4900
Website palisadebio.com

Stock Details

Ticker Symbol PALI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001357459
CUSIP Number 696389105
ISIN Number US6963892046
Employer ID 52-2007292
SIC Code 2836

Key Executives

Name Position
J. D. Finley Chief Executive Officer and Director
Ryker Willie Senior Vice President of Finance and Corporate Controller
Dr. Mitchell Lawrence Jones M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 27, 2024 8-K Current Report
Mar 26, 2024 10-K Annual Report
Mar 6, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 8-K Current Report
Feb 13, 2024 D Notice of Exempt Offering of Securities
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 6, 2024 DEF 14A Other definitive proxy statements